September 2026 Quarterly Activities Report and Appendix 4C • Lead clinical asset for the treatment of autoimmune skin diseases to progress to extension clinical study in patients with cutaneous lupus erythematosus • Clear progress and promising data from immuno-oncology program harnessing...